Splash Beverage reports ~64% reduction in loss from continuing operations for H1 2026
I'm LongbridgeAI, I can summarize articles.Splash Beverage reported a ~64% reduction in loss from continuing operations for H1 2026, dropping to ~$4 million from $11 million year-over-year. This improvement stems from cost-reduction initiatives as the company transitions toward cannabinoid-based pharmaceutical and veterinary opportunities under the new name Endovia Health Sciences. Key developments include an exclusive global license for CannEpil®, a collaboration with Lupvindol Biosciences for veterinary product development, and preparations to relaunch CannEpil® in UK, Ireland, and Latin American markets.
Splash Beverage reported a roughly 64% decline in loss from continuing operations for the six months ended June 30, 2026, driven by cost-reduction initiatives as the company transitions its business. Management cites the improvement from approximately $11 million to approximately $4 million year‑over‑year for the six-month period and is repositioning the company toward cannabinoid-based pharmaceutical and veterinary opportunities. The company announced post‑quarter licensing and collaboration agreements supporting the strategic shift and a planned rebrand to Endovia Health Sciences effective August 24, 2026.
Financial Highlights
- Loss from continuing operations for the six months ended June 30, 2026: approximately $4 million (versus approximately $11 million for the six months ended June 30, 2025).
- Improvement in loss from continuing operations year‑over‑year for the six‑month period: approximately $7 million (approximately 64% improvement).
- Company attributes improvement primarily to significant cost-reduction initiatives implemented over the past six months.
- No specific figures provided in the filing for revenue, gross profit, operating income, net income, or adjusted diluted EPS; those metrics are not reported in the press release.
Business Highlights
- Strategic transformation toward cannabinoid-based health sciences, focusing on pharmaceutical, veterinary and consumer wellness opportunities under the Endovia Health Sciences identity.
- Entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy, providing a foundational pharmaceutical asset.
- Expanded the CannEpil® license to include veterinary applications, initially targeting companion-animal oncology and chronic pain management.
- Executed a development and collaboration agreement with Lupvindol Biosciences Ltd. for Lupvindol to lead scientific and FDA regulatory development of a CannEpil-based veterinary product through the FDA Center for Veterinary Medicine INAD and Conditional Approval pathways.
- Initiated preparations to relaunch CannEpil® through existing commercial and distribution relationships in the United Kingdom, Ireland and select Latin American markets.
- Implemented significant corporate overhead and administrative cost reductions and simplified the company’s operating structure and legacy obligations to create a more efficient platform for the announced strategic initiatives.
Original SEC Filing: SPLASH BEVERAGE GROUP, INC. [ SBEV ] - 8-K - Aug. 20, 2026